Mantis Biotech Raises $6.3 Million Seed Funding to Build Foundational Biomedical Data Platform
Mantis Biotech, a New York–based startup developing infrastructure to unify and validate complex biomedical, clinical, and human performance data for digital twin applications, has announced the successful raise of $6.3 million in a seed funding round as it aims to scale its platform and expand its team and capabilities. The investment was finalized in September 2025, marking a pivotal step for the early‑stage biotech company as it works to streamline data complexity in areas ranging from medical device development to clinical research.
Founded in 2025 by founder Georgia Witchel, Mantis Biotech’s mission is to provide an integrated infrastructure layer that enables companies to build human‑in‑computer models by unifying disparate data sources — such as motion capture, biometric sensors, medical imaging, and training logs — and transforming them into standardized, validated digital twins ready for downstream analytics and production applications. The startup addresses a significant challenge in life sciences and sports tech by helping researchers, developers, and regulatory teams reduce data fragmentation and uncover actionable insights more efficiently.
The seed round was led by Decibel Partners, a venture capital firm focused on deep tech and early‑stage companies, with strong participation from a cadre of well‑known early‑stage backers, including StoryHouse Ventures, Y Combinator (through its Winter 2026 cohort), Pioneer Fund, Spot VC, and Fenwick. These investors bring a mix of domain expertise, startup‑building experience, and ecosystem relationships that are expected to accelerate Mantis Biotech’s development and go‑to‑market strategy.
Decibel Partners’ lead investment underscores confidence in Mantis Biotech’s foundational approach to solving one of the most persistent problems in biotech data infrastructure: fragmentation and poor interoperability. By tackling this bottleneck, Mantis seeks to enable faster, more reliable development cycles for biomedical products and research, reducing time‑to‑insight and improving decision quality across use cases, from sports performance optimization to regulatory submissions.
Y Combinator’s participation highlights the early momentum the company has achieved since joining the prestigious accelerator program. Through its involvement, Mantis gains access to a broad alumni network and mentoring resources that are often critical for scaling early‑stage startups operating at the intersection of biotechnology, AI, and data engineering.
Mantis Biotech plans to deploy the new capital toward expanding its engineering talent, enhancing its data platform’s capabilities, and broadening its enterprise integrations. The company’s unified platform seeks to connect stages of product development — from CAD design and simulation through bench testing and regulatory submissions — into a single traceable environment. This approach is designed to reduce redundant work, cut months off traditional development timelines, and improve compliance through automated verification reporting and documentation generation.
According to company leadership, the infusion of seed funding will also support scaling operations beyond its initial nodes in New York and San Francisco and help broaden Mantis Biotech’s reach into additional verticals, including medical device development and clinical research workflows where the need for consistent, high‑quality data is acute. The startup’s vision reflects a broader industry shift toward “data as infrastructure” — where reliable, interoperable information systems are essential for innovation in life sciences.
The company’s platform transforms fragmented biomedical and clinical data into cohesive, reusable signals usable for analytics, AI model training, and operational workflows. This “data unification” strategy positions Mantis Biotech as a potential backbone for digital twins and other advanced simulation tools that require consistent, reliable inputs from diverse sources.
Investors in the round emphasized their excitement about the startup’s potential to reshape how complex data is managed and leveraged in mission‑critical contexts. Backers such as StoryHouse Ventures and Fenwick bring deep experience in supporting early‑stage technology companies focused on infrastructure and data problems, while Spot VC and others contribute insights from adjacent sectors where AI and data platforms have shown transformative impact.
As Mantis Biotech moves forward with this new funding, the company stands poised to accelerate its product development, expand its technological frontier, and contribute meaningfully to a future where integrated, intelligent biomedical data platforms are essential to scientific and industrial progress.
